-
The medical equipment industry has ushered in major changes, and innovation has become the key to development
Time of Update: 2022-03-05
As a strategic industry supported by the state, China has been increasing its support for the development of the medical device industry in recent years, such as deepening the reform of the medical device review and approval system, encouraging medical device innovation, and continuously improving the quality and efficiency of medical device registration review and approval .
-
The rise of the immune cell therapy track is accelerating, and domestic pharmaceutical companies are accelerating their deployment
Time of Update: 2022-03-05
It is reported that on July 16, 2021, Saiyuan Bio announced the completion of a new round of financing of tens of millions of yuan led by Kunlun Capital to promote the development of its clinical-grade immune cell production process and accelerate other innovations.
-
Pfizer's urgent domestic approval of Paxlovid is good for CDMO suppliers and domestic oral drugs?
Time of Update: 2022-03-05
Junshi Biology announced on December 31 that the Ministry of Health of Uzbekistan has approved the emergency use authorization of its oral nucleoside anti-new coronavirus drug VV116, which shows that VV116 is effective and safe.
-
This year, the field of AI new drugs is still hot, and many pharmaceutical companies choose to "marriage"
Time of Update: 2022-03-04
For example, among multinational pharmaceutical companies, on January 7, Sanofi and Exscientia jointly announced that the two parties had reached an advance payment of 100 million US dollars and a total of about 5.
-
Seeing the Risk of Cell Therapy from the Technical Guiding Principles of CAR-T Clinical Risk Management
Time of Update: 2022-03-04
. From the perspective of targets, both products target CD19, providing a new treatment method for patients with advanced B-cell lymphoma; from the perspective of efficacy, both products have achieved an objective response rate of over 70% in the treatment of DLBCL, and the curative effect Excellent; from a safety point of view, both products are autologous CAR-T cell therapy, free of graft-versus-host disease (GvHD), but both have high levels of cytokine release syndrome (CRS) and neurotoxicity (ICANS) .
-
The drug regulatory system in various places is accelerating the upgrade, and the high-quality development of the pharmaceutical industry has become the general trend
Time of Update: 2022-03-04
In order to further ensure the quality and safety of drugs, since the beginning of this year, many places have issued documents one after another, clearly expressing the need to strengthen the construction of drug supervision capacity and promote the high-quality development of the pharmaceutical industry .
-
8 clinically in short supply drugs are purchased online!
Time of Update: 2022-03-04
According to the requirements of "full online negotiation", the purchase price of clinically in short supply drugs is negotiated by designated medical institutions and drug manufacturers independently .
-
A batch of new pharmaceutical stocks broke intensively, and unprofitable companies accounted for the majority!
Time of Update: 2022-03-04
In the pharmaceutical industry, as of the close on February 16, the newly listed pharmaceutical companies this year, including Asieris Pharmaceuticals, Maiwei Bio and other companies, broke the market on the first day of listing .
-
State Food and Drug Administration: Allow 4 magazines including "Concord Medical Journal" to publish prescription drug advertisements
Time of Update: 2022-03-04
Recently, the State Food and Drug Administration issued a notice on its official website stating that according to the "Advertising Law of the People's Republic of China", after consulting the National Health and Health Commission, it agreed to publish "Concord Medical Journal", "Chinese Journal of Bone and Joint Surgery", and "World Compound Medicine".
-
This disposable consumables factory is expected to be put into production within this year, with a production capacity of 200 million
Time of Update: 2022-03-04
The factory building of about 1,000 square meters can achieve a production capacity of 200 million yuan after completion, which will be used for the development and production of disposable bioreactors, liquid dispensing bags, liquid storage bags and their membrane materials .
-
Shanghai issues notice on online purchase of the first batch of negotiated drugs (self-paying drugs) in 2022
Time of Update: 2022-03-04
The original text is as follows: All relevant units and drug manufacturers: In order to do a good job in the work related to the listing of self-funded drugs on the Internet, in accordance with the "Notice on Printing and Distributing the Implementation Opinions on the Centralized Procurement of Drugs in Public Hospitals in Shanghai" (Hu Ren She Yi [2016] No.
-
Shanghai announces the list of purchases that exceed the "yellow line" by a large margin in December 2021
Time of Update: 2022-03-04
On February 16, Shanghai Yangguan Pharmaceutical Purchasing Network issued the "Notice on Announcement of the List of Purchased Varieties with a Larger Range in the Public Negotiation of Drugs on the Internet in December 2021", involving Citicoline Injection, Injection 2 20 kinds of medicines such as hyprophylline .
-
Jiangsu Provincial Food and Drug Administration issued the third batch of 80 varieties of traditional Chinese medicine formula granules
Time of Update: 2022-03-04
16, 2021) and the relevant regulations of the State Pharmacopoeia Committee on the formulation of drug standards for Chinese medicine formula granules, the Jiangsu Provincial Drug Administration organized the formulation of the third batch of 80 varieties "Jiangsu Province Standard for Chinese Medicine Formula Granules (Trial), to be released for implementation .
-
The CRO sector has risen again, and the competition in this field will become more intense!
Time of Update: 2022-03-03
In fact, in recent years, as the results of the drug administration reform have begun to show, domestic pharmaceutical companies have increased the research and development of innovative drugs, and the domestic pharmaceutical CRO industry has been developing continuously .
-
Baoyuan Pharmaceutical's ROS1/NTRK Inhibitor Obtained Equity of CDE's Proposed Breakthrough Therapy Innovent
Time of Update: 2022-03-03
On September 27, 2021, Baoyuan Medicine and Innovent Bio announced the interim Phase II clinical data of taletrectinib in ROS1-positive non-small cell lung cancer at the 2021 CSCO Conference .
-
During the Spring Festival, how should small and medium-sized chain pharmacies operate?
Time of Update: 2022-03-03
Pharmacy transactions decrease during Chinese New Year During the Spring Festival this year, the situation of chain pharmacies in various places is not optimistic, especially the offline transactions of chain pharmacies are light .
-
Chia Tai Tianqing: Steady Growth in the Future
Time of Update: 2022-03-03
Xie Chengrun, executive director of Sino Biopharmaceuticals and chairman of Chia Tai Tianqing, told reporters that the ultimate goal of policy reform in the medical industry is always to balance patients, medical insurance fund quotas and the development of innovative pharmaceutical companies on the premise of sustainable development of all parties.
-
Pfizer sues Riage Pharma, accusing ex-employee of stealing trade secrets
Time of Update: 2022-03-03
According to Pfizer According to the description of the aspect, its potential advantages include the ability to achieve effective control of blood sugar and body weight, different from oral macromolecular GLP-1RA, not limited by food or dose, and can be developed for single or combined use .
-
Large chains accelerate the layout of "dual-channel" pharmacies
Time of Update: 2022-03-03
86 new drugs are included in the "dual channel", which is good for pharmacies86 new drugs are included in the "dual channel", which is good for pharmaciesOn February 18, the Hunan Provincial Medical Insurance Bureau issued a public announcement, announcing that 86 new drugs in Hunan this year were included in the "dual-channel" single-line payment management .
-
Injections become the protagonist of the seventh batch of national procurement, and the 100 billion market will face a major reshuffle!
Time of Update: 2022-03-03
Among the 27 injection varieties, many are large varieties with market sales exceeding 100 million yuan, including omeprazole injection, cefmetazole injection, cefminox injection, bromhexine injection, edaravone injection, methylprednisolone There are 12 varieties of injections, tigecycline injections, irinotecan injections, clindamycin injections, meropenem injections, octreotide injections, and zoledronic acid injections .
